HOW WAS BALVERSA^® STUDIED?

BALVERSA^® was studied in 266 people with advanced bladder cancer who had tried immunotherapy medicine

A clinical study evaluated patients who had a tumor that tested positive for an FGFR mutation. About half of the people (n=136) received 8 mg BALVERSA^® once daily, while the other half (n=130) received intravenous chemotherapy (docetaxel or vinflunine) once every 3 weeks

After 2 weeks, if people taking BALVERSA^® had phosphate levels below a certain target (determined by a blood test), their dose was increased to 9 mg once daily

People stayed on BALVERSA^® until their tumors started to grow or until they had side effects that were too severe

BALVERSA^® may help you live longer and shrink tumors

Patients lived longer on BALVERSA^® compared with chemotherapy

After 6 months of treatment, 85% of patients receiving BALVERSA^® were still alive

After 12 months of treatment, 51% of patients receiving BALVERSA^® were still alive

• Median overall survival with BALVERSA^® was 12.1 months vs 7.8 months with chemotherapy

More people taking BALVERSA^® saw their tumor shrink compared with chemotherapy

5.1% of people had their tumor disappear completely
(known as a complete response), compared with 0.8%
of people on chemotherapy

30.1% of people had their tumor partially shrink (known as a partial response), compared with 7.7% of people on chemotherapy

5.1% of people had their tumor disappear completely (known as a complete response), compared with 0.8% of people on chemotherapy

30.1% of people had their tumor partially shrink (known as a partial response), compared with 7.7% of people on chemotherapy

Remember, each person is different, so the results you see with BALVERSA^® may not be the same as in the study.